Business Context and Reporting Period
Company: GH Research PLC
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 13, 2026
Context: The Company announced its participation in the 64th American College of Neuropsychopharmacology (ACNP) annual meeting in Nassau, Bahamas (January 12-15, 2026). The filing discloses the presentation of clinical trial results for GH001-TRD-201 by Prof. Michael E. Thase.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate event and clinical data presentation rather than a financial report.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The primary update is the scheduled presentation of clinical data regarding GH001 for patients with Treatment-Resistant Depression.
Guidance, Outlook, and Risks
- Outlook: The Company will present data titled "GH001 Improves Illness Severity, Anxiety Symptoms, and Quality of Life in Patients with Treatment-Resistant Depression."
- Forward-Looking Statements: The Company explicitly states it does not undertake any obligation to update the presentation or forward-looking statements to reflect subsequent actual results.
- Materiality Disclaimer: The availability of the presentation should not be deemed an admission as to the materiality of the information contained therein.
Investor Verification Checklist
- Verify the content of the attached presentation (Exhibit 99.1) regarding GH001-TRD-201 trial results.
- Confirm the specific clinical endpoints (illness severity, anxiety symptoms, quality of life) presented at the ACNP meeting.
- Monitor future filings for any updates on the clinical trial status, as the Company has disclaimed an obligation to update this specific presentation.